a public good project by the
Synthesis
Company
of California

© 2026

Vivian Laquer | doi.page

0 works0 citations0 h-index

Vivian Laquer

George Washington University(US)Orange Coast Memorial Medical Center(US)West Coast Fertility Centers(US)

Publications by Year

Research Areas

Dermatology and Skin Diseases, Psoriasis: Treatment and Pathogenesis, Allergic Rhinitis and Sensitization, Urticaria and Related Conditions, Asthma and respiratory diseases

Most-Cited Works

→ Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis(2023)146 cited
→ Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis(2023)127 cited
→ Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial(2022)71 cited
→ Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials(2023)62 cited
→ Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study(2021)56 cited
→ Angiogenesis in cutaneous disease: Part I(2009)49 cited

→ A phase 3 open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results(2021)

48 cited

→ Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)(2023)47 cited

→ Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis(2022)40 cited

→ Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study(2023)37 cited